A randomized, double‐blind, placebo‐controlled, dose‐escalating phase <scp>IIa</scp> trial to evaluate the safety, tolerability, efficacy, and pharmacokinetics of multiple oral doses of Pynegabine tablets as add‐on therapy in patients with focal epil
Data from the study will be used to evaluate the safety, tolerability, efficacy, and pharmacokinetics of Pynegabine tablets as add-on therapy for focal epilepsy.
Authors
- Huajun Yang (ORCID: https://orcid.org/0000-0001-9888-8375)
- W. Shan (ORCID: https://orcid.org/0000-0003-2811-2218)
- Qun Wang (ORCID: https://orcid.org/0000-0002-5946-2918)
- Weng Shiwen (ORCID: https://orcid.org/0009-0003-2946-4036)
- Chang Cao‐wenjing
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Sanbo Brain Hospital (CN)
- Chinese Institute for Brain Research (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/cns.70002
- Citations
- 2
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- National Natural Science Foundation of China
- Beijing Postdoctoral Science Foundation
- Beijing Nova Program